Spots Global Cancer Trial Database for Contrast-Enhanced Ultrasound Identification of Sentinel Nodes in Esophageal Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Contrast-Enhanced Ultrasound Identification of Sentinel Nodes in Esophageal Cancer

Official Title: Contrast-Enhanced Ultrasound Identification of Sentinel Nodes in Esophageal Cancer

Study ID: NCT03578224

Conditions

Esophagus

Interventions

Endoscopic Ultrasound-Guided Fine-Needle Aspiration (EUS-FNA)

Contrast-Enhanced Ultrasound

Fine-Needle Aspiration

Sonazoid (Perflubutane)

Study Description

Brief Summary: This pilot trial studies how well an ultrasound with a contrast agent (perflubutane microbubble \[Sonazoid\]) works in identifying sentinel lymph nodes in participants with esophageal cancer. Sentinel lymph nodes are lymph nodes to which the cancer is likely to spread from the primary tumor. Diagnostic procedures, such as contrast-enhanced ultrasound, may work better in identifying sentinel lymph nodes and finding out how far the disease has spread.

Detailed Description: PRIMARY OBJECTIVES: I. To assess the accuracy of contrast-enhanced endoscopic lymphosonography guided fine-needle aspiration (FNA) of sentinel lymph nodes compared with unenhanced endoscopic ultrasonography (EUS) guided FNA in the characterization of esophageal cancer-associated lymph nodes using pathology as the reference standard. SECONDARY OBJECTIVES: I. To assess the ability of contrast-enhanced endoscopic lymphosonography guided FNA compared with unenhanced EUS guided FNA in the overall detection of biopsy proven cancer-involved sentinel lymph nodes. II. To assess the impact of overall tumor staging by contrast-enhanced endoscopic lymphosonography compared with unenhanced EUS.